Victory Capital Management
ZNTL icon

Victory Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Victory Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,747
Closed -$399K – 2821
2021
Q4 		$399K Sell
4,747
-187
-4% -$14.5K ﹤0.01% 2272
2021
Q3 		$329K Buy
4,934
+898
+22% +$51.8K ﹤0.01% 2353
2021
Q2 		$215K Buy
+4,036
New +$216K ﹤0.01% 2514

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Victory Capital Management's ZNTL Position: Q1 2022 in Review

Victory Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 4,747 shares — an estimated $399K sold.

Victory Capital Management first reported a position in ZNTL in Q2 2021 and held it in 3 quarters. The position peaked at $399K in Q4 2021. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

  • Victory Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Victory Capital Management sold 4,747 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $399K.
  • Victory Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Victory Capital Management's Zentalis Pharmaceuticals position peaked at $399K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.